Physician profile
Jacqueline Schultz
NPI 1548440431
$1,841.55
in general payments reported to CMS, 2019-2025
21 companies · $444 in 2025
The $444 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.37 · 2022: $29.83 · 2023: $490 · 2024: $866 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,442 · Education: $357.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,442.37 |
| Education | $356.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $484.72 | 2022-2024 | Tremfya |
| Arcutis Biotherapeutics, INC. | $249.39 | 2023-2024 | Zoryve |
| Dermavant Sciences, INC. | $179.11 | 2023-2024 | Vtama |
| Amgen INC. | $173.52 | 2024-2025 | Otezla, Otezla |
| Sun Pharmaceutical Industries INC. | $154.17 | 2022-2024 | Winlevi |
| Genzyme Corporation | $89.62 | 2023-2025 | |
| Janssen Scientific Affairs, LLC | $66.35 | 2023 | Tremfya |
| Journey Medical Corporation | $60.82 | 2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $50.92 | 2023-2025 | Cabtreo, Arazlo |
| Mayne Pharma Commercial LLC | $47.71 | 2023-2024 | |
| Organon LLC | $44.58 | 2025 | Vtama |
| Abbvie INC. | $43.61 | 2021-2025 | |
| Pfizer INC. | $34.40 | 2024-2025 | |
| Leo Pharma INC. | $27.89 | 2023-2024 | Adbry |
| Novartis Pharmaceuticals Corporation | $24.18 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Convatec INC. | $23.09 | 2025 | |
| Lilly USA, LLC | $18.95 | 2023 | Taltz, Olumiant |
| Regeneron Healthcare Solutions, INC. | $18.49 | 2025 | Libtayo |
| Verrica Pharmaceuticals INC. | $17.00 | 2023 | Ycanth |
| Ucb, INC. | $16.88 | 2024 | Bimzelx |
| Galderma Laboratories, L.P. | $16.15 | 2025 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.